Meilan Chen

Longitudinal Flow Cytometry Identified “Minimal Residual Disease” (MRD) Evolution Patterns for Predicting the Prognosis of Patients with Transplant-Eligible Multiple Myeloma

Jingli Gu, Junru Liu, Meilan Chen et al. · Biology of Blood and Marrow Transplantation · 2018 · 48 citations · Full text

Medicine, Hematology, Oncology +14

1q21 Gain Combined with High-Risk Factors Is a Heterogeneous Prognostic Factor in Newly Diagnosed Multiple Myeloma: A Multicenter Study in China

Xiaozhe Li, Wen-Ming Chen, Yin Wu et al. · The Oncologist · 2019 · 31 citations · Full text

Life Sciences, Genetics, Oncology +13

Health‐related quality of life of patients with multiple myeloma: A real‐world study in China

Xiaozhe Li, Junru Liu, Meilan Chen et al. · Cancer Medicine · 2020 · 21 citations · Full text

Medicine, Hematology, Oncology +16

Application of PET/CT in treatment response evaluation and recurrence prediction in patients with newly-diagnosed multiple myeloma

Ying Li, Junru Liu, Beihui Huang et al. · Oncotarget · 2016 · 13 citations · Full text

Medicine, Oncology, Radiology +17

Comparison of efficacy, safety, patients’ quality of life, and doctors’ occupational stress between lenalidomide‐based and bortezomib‐based induction in patients with newly diagnosed multiple myeloma

Limei Xu, Junru Liu, Beihui Huang et al. · Cancer Medicine · 2021 · 11 citations · Full text

Medicine, Oncology, Pharmacotherapy +13